Where could CANF trade next? Consensus target price: $8.
Get informed when a big investor buys or sells
+ Follow$2.17
1 analysts in the last 4 months
High: $8 | Low: $8
No recommendations in the last 4 months.
The latest target price for CANF is $8. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.
Can-Fite Biopharma trades near $2.17 while the consensus target sits at $8 (268.7% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.
After noting CANF's target price ($8), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.